Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News & Events

: Press Releases

Home
News & Events
Press Releases

Press Releases

Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

August 21, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

August 15, 2018 • 11:46 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

August 13, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

July 27, 2018 • 8:00 AM EDT

Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease

July 16, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology

May 31, 2018 • 4:30 PM EDT

Tonix Pharmaceuticals to Present at the 2018 BIO International Convention

May 30, 2018 • 8:00 AM EDT

Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL

May 24, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology

May 23, 2018 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

May 14, 2018 • 7:00 AM EDT

« Previous
1
2
3
4
5
6
7
8
9
10
...28
Next »

News & Events : Press Releases